Live Breaking News & Updates on Translational Clinical Oncology

Stay updated with breaking news from Translational clinical oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director

Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , City Of , United Kingdom , Sonia Quaratino , Sue Charles , Eduardo Bravo , Charles Consultants , Mike Platt , Giuseppe Mazza , Merck Serono , Division Of Medicine , Ichnos Sciences , University College London , University Of Southampton , University Of Palermo , Digestive Health , Engitix Ltd , Imperial College London , Institute For Liver , Chief Medical Officer , Clinical Advisory Board , Global Clinical Program Leader , Translational Clinical Oncology , Senior Medical Director , Immunology Advisor , Medical Degree ,

Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology

Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United Kingdom , City Of , Kristen Albright , Mario Brkulj , Merck Kga , Kostenloser Wertpapierhandel , Uz Stammberger , Novartis Institutes For Biomedical Research , Boehringer Ingelheim , University Of Bern , Chief Medical , Chief Medical Officer , Business Wire , Chief Executive Officer , Novartis Institutes , Biomedical Research , Translational Clinical Oncology , Clinical Lead , General Thoracic Surgery , Executive Officer , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , கிறிஸ்டன் ஆல்பிரைட் , மெர்க் க்க , நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி , போஹெரிங்கர் இஂகல்‌ஹைம் ,

Blueprint Medicines Announces R&D Leadership Transitions

Blueprint Medicines Announces R&D Leadership Transitions
Becker Hewes, M.D., promoted to Chief Medical Officer
Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development
Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company s research and development organization. Effective as of January 11, 2021, Becker Hewes, M.D., currently Senior Vice President, Clinical Development, will succeed Andy Boral, M.D., Ph.D., as Chief Medical Officer, and Dr. Boral will transition to a new role as Executive Vice President, Clinical Development. With his promotion, Dr. Hewes will be responsible for clinical development, clinical operations, pharmacovigilance, translational medicine and bi ....

United States , United Kingdom , Marion Dorsch , Fouad Namouni , Becker Hewes , Blueprint Medicines Corporation , Research Development At Blueprint Medicines , Novartis Institutes For Biomedical Research , Wyeth Pharmaceuticals , Research Development , Georgetown University School Of Medicine , Prnewswire Blueprint Medicines Corporation , Emory Vaccine Center , Vanderbilt University , Clinical Development , Genzyme Corporation , Medicines Corporation , Senior Vice President , Andy Boral , Chief Medical Officer , Executive Vice President , Blueprint Medicines , Chief Scientific Officer , Blueprint Medicine Senior Vice President , Repertoire Immune Medicines , Torque Therapeutics ,

Clinical Challenges: ALK-Positive NSCLC

EML4), producing a unique ALK protein that promotes unchecked, abnormal cell growth.
We see it in about 4-5% of our non-small cell lung cancer patients, so it s a small slice of that pie, Shaw told
Medpage Today. But there are so many non-small lung cell cancer patients out there that even 4-5% is still a large absolute number of patients. And that s not just in the U.S., but worldwide.
The development of targeted therapies for
ALK-positive NSCLC over the past dozen years has had a significant impact on the natural history of the disease. According to Shaw, in the absence of the ALK targeted therapies, ....

United States , Alice Shaw , Jose Pacheco , Novartis Institutes For Biomedical Research , University Of Colorado School Medicine , Translational Clinical Oncology , Novartis Institutes , Biomedical Research , Thoracic Cancers , Massachusetts General Hospital , Colorado School , ஒன்றுபட்டது மாநிலங்களில் , ஆலிஸ் ஷா , ஜோசே ப்யாயேகோ , நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி , பல்கலைக்கழகம் ஆஃப் கொலராடோ பள்ளி மருந்து , மொழிபெயர்ப்பு மருத்துவ புற்றுநோயியல் , நோவர்த்திச் நிறுவனங்கள் , உயிர் மருத்துவ ஆராய்ச்சி , தொராசி புற்றுநோய்கள் , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , கொலராடோ பள்ளி ,